Maze Therapeutics, Inc.’s (NASDAQ:MAZE) Quiet Period Will End on March 12th

Maze Therapeutics’ (NASDAQ:MAZE) quiet period is set to expire on Wednesday, March 12th. Maze Therapeutics had issued 8,750,000 shares in its initial public offering on January 31st. The total size of the offering was $140,000,000 based on an initial share price of $16.00. During Maze Therapeutics’ quiet period, insiders and any underwriters that worked on the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Analysts Set New Price Targets

A number of research firms have recently weighed in on MAZE. Guggenheim began coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They issued a “buy” rating and a $19.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They issued an “overweight” rating and a $30.00 price target for the company. TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Tuesday, February 25th. Leerink Partners assumed coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set an “outperform” rating and a $28.00 price target on the stock. Finally, Leerink Partnrs raised Maze Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 25th. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $25.67.

Maze Therapeutics Price Performance

Shares of Maze Therapeutics stock opened at $11.73 on Friday. Maze Therapeutics has a one year low of $10.08 and a one year high of $17.00.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.